Multiple sclerosis (MS) is the most frequent chronic neurological disease in the world. MS is seen as the inflammation of the central nervous system (CNS). MS patients are routinely treated with immunosuppressive medications when it is discovered which is medicine to help regulate the immune system. Cannabidiol (CBD) is a a constituent of the cannabis plant and may be used therapeutically to treat patients with MS due to the lack of psychoactive properties. MS models that show inflammation and brain damage have been treated with CBD cannabis and this has had a positive effect on these symptoms with no side effects. Sativex, a therapeutic spray that contains small doses of CBD and tetrahydrocannabinol (THC), another constituent of cannabis, is currently used for the treatment of symptoms of MS, particularly muscle spasms and head related pain. This paper will look at how medical marijuana can help with MS treatment.
Here is the full scientific article if you wish to download it.
In the central nervous system (CNS), CBD has been shown to act as a cell protector and to reduce inflammation. In a model of multiple sclerosis by Kozela et al., 2011, mice were treated with C.sativa, a cannabis based derivative, and it showed that it can have a positive therapeutic effect while reducing inflammation, microglial activity and leukocyte homing in the spinal cord. All these properties point out that the effects of cannabis are positive in the treatment of neuroinflammatory disorders like MS.
Pioneer works by Hampson, Grimaldi, Axelrod, and Wink (1998) showed that CBD and THC have anti oxidising properties and this promotes good cell growth. Hampson et al. (1998) illustrated that when CBD is exerted into a subject, Vitamin E and C are able to work more efficiently in getting rid of damaging oxidising agents. These observations suggest that CBD may be a potential therapeutic agent for the treatment of oxidative neurological disorders like cerebral ischemia.
Because of the interest of CBD in brain related diseases such as Huntington’s, epilepsy and schizophrenia, there are studies now administering medical cannabis at different doses to healthy volunteers by oral or IV route. The paper encourages futures studies in clinical applications of oral CBD for patients with progressive MS and in how smoking cannabis could help the disease over a long term period. Overall, CBD lacks any unwanted psychotropic effects and may represent a promising treatment option for therapeutic use in MS patients but this needs to be studied further.